Preclinical studies in murine cancer models have shown that CSF1R inhibitors can block the increased secretion of various cytokines in TME, leading to decreased MDSC accumulation, angiogenesis, and tumor burden (Mao et al., 2016; Priceman et al., 2010; Webb et al., 2018). Here, CSF1R is linked to neoplasm.